Regulus Therapeutics Inc.
RGLS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $89 | $24 | $21 | $27 |
| - Cash | $39 | $24 | $24 | $60 |
| + Debt | $0 | $2 | $6 | $7 |
| Enterprise Value | $51 | $3 | $3 | -$26 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | -$0 | -$21 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$46 | -$31 | -$28 | -$27 |
| % Margin | – | – | – | – |
| Net Income | -$46 | -$30 | -$28 | -$28 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.82 | -1.58 | -1.86 | -3.24 |
| % Growth | 48.1% | 15.1% | 42.6% | – |
| Operating Cash Flow | -$42 | -$27 | -$26 | -$24 |
| Capital Expenditures | -$0 | -$1 | -$0 | -$0 |
| Free Cash Flow | -$42 | -$27 | -$26 | -$24 |